银屑病的生物治疗（第一部分）：肿瘤坏死因子-α抑制剂的疗效与安全性
Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
作者信息
Campanati Anna, Molinelli Elisa, Brisigotti Valerio, Offidani Annamaria
机构信息
Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
出版信息
Curr Pharm Biotechnol. 2017;18(12):945-963. doi: 10.2174/1389201019666180209121804.
BACKGROUND
Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored.
METHODS
Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)- 12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
RESULTS
In this section, we explore the complex role of TNFα in psoriasis as well as the efficacy and safety of TNFα inhibitors largely used in the management of the cutaneous disease.
CONCLUSION
Dosing regimens, administration, pharmacodynamics profiles, efficacy, and safety of licensed anti-TNFα are here discussed in detail.
背景
银屑病是一种慢性免疫介导的炎症性疾病，全球估计患病率为2%-3%。银屑病与健康相关生活质量受损及巨大的经济负担相关。针对银屑病发病机制中相关通路的生物制剂是中重度斑块状银屑病的既定治疗方法，其卓越的疗效和安全性已得到广泛研究和监测。
方法
目前可用的生物疗法主要可分为三大类：肿瘤坏死因子α（TNFα）拮抗剂（英夫利昔单抗、阿达木单抗、依那西普、戈利木单抗、赛妥珠单抗）、白细胞介素（IL）-12/23单克隆抗体（乌司奴单抗）和IL-17抑制剂（司库奇尤单抗、依奇珠单抗）。
结果
在本节中，我们探讨了TNFα在银屑病中的复杂作用以及在治疗该皮肤病中广泛使用的TNFα抑制剂的疗效和安全性。
结论
本文详细讨论了已获批的抗TNFα药物的给药方案、给药方式、药效学特征、疗效和安全性。
Zotero 插件